Teva Pharmaceuticals
TEVA
542 hedge funds and large institutions have $11.3B invested in Teva Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 73 funds opening new positions, 195 increasing their positions, 172 reducing their positions, and 58 closing their positions.
185% more call options, than puts
Call options by funds: $498M | Put options by funds: $175M
26% more first-time investments, than exits
New positions opened: 73 | Existing positions closed: 58
14% more capital invested
Capital invested by funds: $9.88B → $11.3B (+$1.38B)
13% more repeat investments, than reductions
Existing positions increased: 195 | Existing positions reduced: 172
12% more funds holding in top 10
Funds holding in top 10: 25 → 28 (+3)
2.45% more ownership
Funds ownership: 53.68% → 56.13% (+2.5%)
2% more funds holding
Funds holding: 533 → 542 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$363M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$159M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$132M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$82.8M |
| 5 |
William Blair Investment Management
Chicago,
Illinois
|
+$76.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Slate Path Capital
New York
|
-$114M |
| 2 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
-$63.9M |
| 3 |
JP Morgan Chase
New York
|
-$52.7M |
| 4 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$50.1M |
| 5 |
Truist Financial
Charlotte,
North Carolina
|
-$43.7M |
TEVA Hedge Fund Activity: Q3 2024 in Review
542 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2024, worth a combined $11.3B — up 14% from $9.88B a quarter earlier.
Buyers outnumbered sellers: 73 funds opened new TEVA positions and 58 closed out — a net gain of 15 holders — while 195 added to existing stakes and 172 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $363M. The largest seller was Slate Path Capital, cutting an estimated $114M.
- 542 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2024, up from 533 in Q2 2024.
- Funds reported $11.3B of Teva Pharmaceuticals stock for Q3 2024, up 14% quarter-over-quarter.
- 73 funds opened new Teva Pharmaceuticals positions in Q3 2024 and 58 closed out, a net change of +15 holders.
- The largest Teva Pharmaceuticals buyer in Q3 2024 was Fidelity Investments, an estimated $363M added.
- The largest Teva Pharmaceuticals seller in Q3 2024 was Slate Path Capital, an estimated $114M sold.
Based on aggregated 13F filings for Q3 2024.